JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock

Key Points

• JPMorgan raised Establishment Labs’ price target to $95 from $84 and maintained an “overweight” rating, implying 19.72% upside. The broader analyst consensus is “Moderate Buy,” with an average target of $100.25.
• Establishment Labs reported quarterly revenue of $67.54 million, up 31.7% year over year and above expectations, while its loss narrowed from the prior year. However, the $0.39-per-share loss was wider than analysts’ $0.34 estimate, and the company remains unprofitable.
• Management projected 2026 revenue of $269 million to $271 million, above consensus, while minimally invasive procedures approached 15% of sales. Institutional investors own 72.91% of the stock, indicating substantial interest from major funds.

Establishment Labs (NASDAQ:ESTA - Get Free Report) had its price target increased by JPMorgan Chase & Co. from $84.00 to $95.00 in a report issued on Friday,Benzinga reports. The firm currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target indicates a potential upside of 19.72% from the company's current price.

ESTA has been the topic of several other reports. Citigroup increased their price target on shares of Establishment Labs from $76.00 to $92.00 and gave the company a "neutral" rating in a report on Wednesday, July 8th. Canaccord Genuity Group set a $105.00 target price on Establishment Labs in a research report on Thursday. BTIG Research increased their target price on Establishment Labs from $96.00 to $103.00 and gave the stock a "buy" rating in a research note on Thursday. Needham & Company LLC lifted their price target on Establishment Labs from $86.00 to $95.00 and gave the stock a "buy" rating in a report on Thursday. Finally, TD Cowen boosted their target price on shares of Establishment Labs from $95.00 to $117.00 and gave the company a "buy" rating in a research report on Monday. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $100.25.

Establishment Labs Stock Performance

ESTA stock traded up $0.30 during midday trading on Friday, reaching $79.35. 283,373 shares of the company were exchanged, compared to its average volume of 552,277. Establishment Labs has a one year low of $33.35 and a one year high of $97.59. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of -53.29 and a beta of 1.07. The business has a 50-day moving average price of $86.29 and a two-hundred day moving average price of $74.23. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The company had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. Establishment Labs's revenue for the quarter was up 31.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.57) earnings per share. Equities research analysts forecast that Establishment Labs will post -1.07 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its holdings in shares of Establishment Labs by 117.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company's stock valued at $59,145,000 after purchasing an additional 438,206 shares during the last quarter. Viking Global Investors LP acquired a new stake in Establishment Labs in the second quarter valued at approximately $14,669,000. Soleus Capital Management L.P. acquired a new stake in Establishment Labs in the second quarter valued at approximately $9,050,000. Summit Partners Public Asset Management LLC grew its stake in shares of Establishment Labs by 87.1% during the third quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company's stock worth $17,632,000 after buying an additional 200,255 shares during the last quarter. Finally, Nantahala Capital Management LLC grew its stake in shares of Establishment Labs by 11.1% during the third quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company's stock worth $80,893,000 after buying an additional 197,962 shares during the last quarter. 72.91% of the stock is owned by institutional investors.

Key Headlines Impacting Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Management projected 2026 revenue of $269 million to $271 million, above the approximately $267.5 million analyst consensus. The company also said minimally invasive procedures are approaching 15% of sales, highlighting adoption of a potentially important growth area. Establishment Labs signals 2026 revenue guidance
• Positive Sentiment: Second-quarter revenue reached $67.54 million, exceeding the $65.79 million consensus estimate and increasing 31.7% from the prior-year period. The company’s loss narrowed to $0.39 per share from $0.57 a year earlier, despite missing estimates. Establishment Labs Q2 results
• Positive Sentiment: BTIG Research raised its price target from $96 to $103 and reaffirmed a Buy rating. Needham also lifted its target from $86 to $95 and assigned a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Needham raises Establishment Labs price target
• Negative Sentiment: ESTA reported a quarterly loss of $0.39 per share, wider than the expected $0.34 loss. The company remains unprofitable, with a negative net margin, so investors may focus on the pace of earnings improvement and the path to profitability.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source